Table 5.

Meta-Analysis of the Association Between MDM2 rs937283 Variant and Cancer Susceptibility.

Genetic Model	Heterogeneity Test			Summary OR (95% CI)	Hypothesis Test		Begg Test		Egger Test		Studies (n)
	Q	P	I 2		Z	P	z	P	T	P
rs937283 and cancer susceptibility
G vs A	38.7	<1 × 10−3	66%	1.17 (1.06-1.30)	3.00	.003	1.16	.246	1.75	.222	14
GG vs AA	28.9	.007	55%	1.30 (1.04-1.62)	2.34	.019	1.77	.077	2.15	.054	14
AG vs AA	30.2	.004	57%	1.18 (1.04-1.34)	2.55	.011	0.55	.583	1.62	.134	14
GG + AG vs AA	36.2	.001	64%	1.21 (1.06-1.38)	2.84	.004	0.43	.669	2.03	.067	14
GG vs AG + AA	22.7	.045	43%	1.18 (0.99-1.42)	1.82	.069	1.65	.100	2.05	.064	14
rs937283 and cancer susceptibility in Asian
G vs A	15.6	.029	55%	1.30 (1.13-1.49)	3.65	<1 × 10−3	0.12	.902	1.42	.206	8
GG vs AA	14.5	.044	52%	1.64 (1.12-2.42)	2.51	.012	0.37	.711	0.28	.792	8
AG vs AA	5.37	.615	0%	1.26 (1.13-1.41)	4.04	<1 × 10−3	0.37	.711	1.76	.130	8
GG + AG vs AA	9.91	.194	29%	1.30 (1.17-1.44)	4.81	<1 × 10−3	0.12	.902	1.58	.165	8
GG vs AG + AA	12.5	.085	44%	1.51 (1.06-2.15)	2.27	.023	−0.12	1.000	0.14	.897	8
rs937283 and cancer susceptibility in Caucasian
G vs A	7.46	.189	33%	1.01 (0.94-1.09)	0.32	.748	0.75	.452	1.53	.201	6
GG vs AA	5.35	.375	6.5%	1.02 (0.88-1.18)	0.30	.765	1.13	.260	2.01	.114	6
AG vs AA	17.8	.003	72%	1.08 (0.86-1.35)	0.63	.529	0.75	.452	0.91	.414	6
GG + AG vs AA	16.1	.007	69%	1.08(0.88-1.33)	0.73	.468	0.75	.452	1.17	.309	6
GG vs AG + AA	3.08	.688	0%	1.01 (0.89-1.15)	0.12	.904	1.13	.260	1.19	.301	6

Abbreviations: CI, confidence interval; OR, odds ratio.